CELEX: 62019TA0817
Language: en
Date: 2021-01-27 00:00:00
Title: Case T-817/19: Judgment of the General Court of 27 January 2021 — Olimp Laboratories v EUIPO — OmniVision (Hydrovision) (EU trade mark — Opposition proceedings — Application for EU figurative mark Hydrovision — Earlier EU word mark Hylo-Vision — Relative ground for refusal — Likelihood of confusion — Article 8(1)(b) of Regulation (EC) No 207/2009 (now Article 8(1)(b) of Regulation (EU) 2017/1001))

15.3.2021   
            
            
               EN
            
            
               Official Journal of the European Union
            
            
               C 88/28
            
         
      Judgment of the General Court of 27 January 2021 — Olimp Laboratories v EUIPO — OmniVision (Hydrovision)
      (Case T-817/19) (1)
      
      (EU trade mark - Opposition proceedings - Application for EU figurative mark Hydrovision - Earlier EU word mark Hylo-Vision - Relative ground for refusal - Likelihood of confusion - Article 8(1)(b) of Regulation (EC) No 207/2009 (now Article 8(1)(b) of Regulation (EU) 2017/1001))
      (2021/C 88/36)
      Language of the case: English
      
         Parties
      
      
         Applicant: Olimp Laboratories sp. z o.o. (Dębica, Poland) (represented by: M. Kondrat, lawyer)
      
         Defendant: European Union Intellectual Property Office (represented by: D. Walicka, acting as Agent)
      
         Other party to the proceedings before the Board of Appeal of EUIPO, intervener before the General Court: OmniVision GmbH (Puchheim, Germany) (represented by: B. Sorg, D. Wiedemann and M. Ringer, lawyers)
      
         Re:
      
      Action brought against the decision of the Second Board of Appeal of EUIPO of 13 September 2019 (Case R 2371/2018 2), relating to opposition proceedings between OmniVision and Olimp Laboratories.
      
         Operative part of the judgment
      
      The Court:
      
                  1.
               
               
                  Dismisses the action;
               
            
                  2.
               
               
                  Orders Olimp Laboratories sp z o.o. to pay the costs.
               
            
         (1)  OJ C 27, 27.1.2020.